Nicola Ferrari, Translational Science Director at AstraZeneca, shared a post on LinkedIn about a recent article by Alexander L. Ling et al. published in Science Translational Medicine:
“Serial multiomics uncovers anti-glioblastoma responses not evident by routine clinical analyses
Glioblastomas (GBM) remains an incurable and aggressive brain cancer with a very poor prognosis; the 2-year survival rate stands currently at 5%.
Assessing tumor growth is essential to both diagnosing and treating incurable glioblastomas. Until now, monitoring of tumor growth has been limited to the use of magnetic resonance imaging (MRI).
Here, the authors conducted a feasibility study of serial multiomic analyses of recurrent GBM biopsies from two patients treated with an oncolytic immunotherapeutic agent.
From the first two patients, 97 serial multisector biopsies were collected and analyzed by multiomics, including immunofluorescence, single-cell RNA sequencing, proteomics, phosphoproteomics, immunopeptidomics, and tumor T cell clonotype characterization, as well as routine histopathology.
Despite MRI-diagnosed tumor progression in these participants, multiomic analyses showed evidence of therapeutic effects and immune activation in both patients with increases in inflammatory cells, plasma cells, lymphocytes, and mononuclear cells accompanied by decreased tumor presence compared with baseline data.
Both patients showed positive clinical outcomes (pathologic response or stable disease), challenging reliance on conventional imaging for assessing immunotherapy efficacy in GBM.
This study, although limited to two patients, demonstrates the value of longitudinal tissue sampling and multiomic profiling to understand GBM’s complex evolution.”
Title: Serial multiomics uncovers anti-glioblastoma responses not evident by routine clinical analyses
Authors: Alexander L. Ling, Jennifer Gantchev, Michael C. Prabhu, Sreyashi Basu, Ryuhjin Ahn, Alicia D’Souza, Nafisa Masud, Anna Ball, Odysseas Nikas, Genaro R. Villa, Michael S. Regan, Gerard Baquer, Georges Ayoub, Charles A. Whittaker, Zaki Abou-Mrad, Andres Santos, Charles P. Couturier, Dina Elharouni, Jayne Vogelzang, Kenny K. H. Yu, Hong Chen, Zhong He, Wen Jiang, Calixto Hope Lucas, Haley E. Sax, Frederick F. Lang, Vinay K. Puduvali, Viviane Tabar, Cameron W. Brennan, Adrienne Boire, Matthias Holdhoff, Chetan Bettegowda, Michael Cima, Isaac H. Solomon, Ying Yuan, Paul P. Tak, Accelerating GBM Therapies TeamLab, Padmanee Sharma, Forest M. White, Keith L. Ligon, Nathalie Y.R. Agar, David A. Reardon, Giacomo Oliveira, E. Antonio Chiocca
Read the Full Article on Science Translational Medicine
More posts featuring Nicola Ferrari.
